High-throughput Rational Design of the Remdesivir Binding Site in the RdRp of SARS-CoV-2: Implications for Potential Resistance

Overview

Journal iScience

Publisher Cell Press

Date 2021 Jan 25

PMID 33490902

Citations 48

Authors

Aditya K Padhi

Rohit Shukla

Prakash Saudagar

Timir Tripathi

Affiliations

Soon will be listed here.

Abstract

The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of remdesivir resistance. Using a rational ligand-based interface design complemented with mutational mapping, we generated a total of 100,000 mutations and provided insight into the functional outcomes of mutations in the remdesivir-binding site in nsp12 subunit of RdRp. After designing 46 residues in the remdesivir-binding site of nsp12, the designs retained 97%-98% sequence identity, suggesting that very few mutations in nsp12 are required for SARS-CoV-2 to attain remdesivir resistance. Several mutants displayed decreased binding affinity to remdesivir, suggesting drug resistance. These hotspot residues had a higher probability of undergoing selective mutation and thus conferring remdesivir resistance. Identifying the potential residues prone to mutation improves our understanding of SARS-CoV-2 drug resistance and COVID-19 pathogenesis.

Citing Articles

SARS-CoV-2 drug resistance and therapeutic approaches.

Batool S, Chokkakula S, Jeong J, Baek Y, Song M Heliyon. 2025; 11(2):e41980.

PMID: 39897928 PMC: 11786845. DOI: 10.1016/j.heliyon.2025.e41980.

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination.

Anglero-Rodriguez Y, Lempp F, Subramanian M, McIninch J, Schlegel M, Bohan D Nucleic Acids Res. 2024; 53(1.

PMID: 39657790 PMC: 11724309. DOI: 10.1093/nar/gkae1195.

Recent Advances of Nipah Virus Disease: Pathobiology to Treatment and Vaccine Advancement.

Saha S, Bhattacharya M, Lee S, Chakraborty C J Microbiol. 2024; 62(10):811-828.

PMID: 39292378 DOI: 10.1007/s12275-024-00168-3.

Computational investigation of novel synthetic analogs of C-1'β substituted remdesivir against RNA-dependent RNA-polymerase of SARS-CoV-2.

Cardoza S, Singh A, Sur S, Singh M, Dubey K, Samanta S Heliyon. 2024; 10(17):e36786.

PMID: 39286185 PMC: 11402944. DOI: 10.1016/j.heliyon.2024.e36786.

Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.

Das S, Nath S, Shahjahan , Dey S Daru. 2024; 32(2):801-823.

PMID: 39026019 PMC: 11554973. DOI: 10.1007/s40199-024-00524-z.

References

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Callaway E . The coronavirus is mutating - does it matter?. Nature. 2020; 585(7824):174-177. DOI: 10.1038/d41586-020-02544-6. View

Romero P, Arnold F . Exploring protein fitness landscapes by directed evolution. Nat Rev Mol Cell Biol. 2009; 10(12):866-76. PMC: 2997618. DOI: 10.1038/nrm2805. View

Goldhill D, Te Velthuis A, Fletcher R, Langat P, Zambon M, Lackenby A . The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A. 2018; 115(45):11613-11618. PMC: 6233120. DOI: 10.1073/pnas.1811345115. View

Furuta Y, Gowen B, Takahashi K, Shiraki K, Smee D, Barnard D . Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013; 100(2):446-54. PMC: 3880838. DOI: 10.1016/j.antiviral.2013.09.015. View

Moretti R, Bender B, Allison B, Meiler J . Rosetta and the Design of Ligand Binding Sites. Methods Mol Biol. 2016; 1414:47-62. PMC: 5511788. DOI: 10.1007/978-1-4939-3569-7_4. View

Counago R, Chen S, Shamoo Y . In vivo molecular evolution reveals biophysical origins of organismal fitness. Mol Cell. 2006; 22(4):441-9. DOI: 10.1016/j.molcel.2006.04.012. View

Wu F, Zhao S, Yu B, Chen Y, Wang W, Song Z . A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798):265-269. PMC: 7094943. DOI: 10.1038/s41586-020-2008-3. View

Te Velthuis A, Arnold J, Cameron C, van den Worm S, Snijder E . The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2009; 38(1):203-14. PMC: 2800238. DOI: 10.1093/nar/gkp904. View

10.

Padhi A, Tripathi T . Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity?. ACS Pharmacol Transl Sci. 2020; 3(5):1023-1026. PMC: 7551720. DOI: 10.1021/acsptsci.0c00113. View

11.

Shannon A, Le N, Selisko B, Eydoux C, Alvarez K, Guillemot J . Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020; 178:104793. PMC: 7151495. DOI: 10.1016/j.antiviral.2020.104793. View

12.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

13.

Uversky V . A decade and a half of protein intrinsic disorder: biology still waits for physics. Protein Sci. 2013; 22(6):693-724. PMC: 3690711. DOI: 10.1002/pro.2261. View

14.

Reeve S, Gainza P, Frey K, Georgiev I, Donald B, Anderson A . Protein design algorithms predict viable resistance to an experimental antifolate. Proc Natl Acad Sci U S A. 2015; 112(3):749-54. PMC: 4311853. DOI: 10.1073/pnas.1411548112. View

15.

Andersen K, Rambaut A, Lipkin W, Holmes E, Garry R . The proximal origin of SARS-CoV-2. Nat Med. 2020; 26(4):450-452. PMC: 7095063. DOI: 10.1038/s41591-020-0820-9. View

16.

Fleishman S, Leaver-Fay A, Corn J, Strauch E, Khare S, Koga N . RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS One. 2011; 6(6):e20161. PMC: 3123292. DOI: 10.1371/journal.pone.0020161. View

17.

Ahn D, Choi J, Taylor D, Oh J . Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates. Arch Virol. 2012; 157(11):2095-104. PMC: 7086750. DOI: 10.1007/s00705-012-1404-x. View

18.

Ziebuhr J . The coronavirus replicase. Curr Top Microbiol Immunol. 2004; 287:57-94. PMC: 7121973. DOI: 10.1007/3-540-26765-4_3. View

19.

Tchesnokov E, Feng J, Porter D, Gotte M . Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019; 11(4). PMC: 6520719. DOI: 10.3390/v11040326. View

20.

Lehmann K, Gulyaeva A, Zevenhoven-Dobbe J, Janssen G, Ruben M, Overkleeft H . Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res. 2015; 43(17):8416-34. PMC: 4787807. DOI: 10.1093/nar/gkv838. View